Brief: Cogent Biosciences Announces Positive Initial Data From Phase 2 Summit Trial Evaluating Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)
09/12/2023 23:55
Dec 9 (Reuters) - Cogent Biosciences Inc COGT.O :
* COGENT BIOSCIENCES ANNOUNCES POSITIVE INITIAL DATA FROM
PHASE 2
SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH
NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM)
Source text for Eikon: ID:nGNX5VJcCf
Further company coverage: COGT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's